Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

718 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, Ferrero S, Sgherza N, Mazzone AM, Marino D, Calimeri T, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F; Fondazione Italiana Linfomi Postgraduate Master Course. Olivieri J, et al. Among authors: olivieri a. Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29. Biol Blood Marrow Transplant. 2018. PMID: 29857196 Free article.
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Corradini P, et al. Among authors: olivieri a. Blood. 2002 Jan 1;99(1):75-82. doi: 10.1182/blood.v99.1.75. Blood. 2002. PMID: 11756155 Free article.
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P. Olivieri A, et al. Biol Blood Marrow Transplant. 2005 Aug;11(8):627-36. doi: 10.1016/j.bbmt.2005.05.002. Biol Blood Marrow Transplant. 2005. PMID: 16041313 Free article.
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P. Offidani M, et al. Among authors: olivieri a. Haematologica. 2006 Jan;91(1):133-6. Haematologica. 2006. PMID: 16434383 Clinical Trial.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Offidani M, et al. Among authors: olivieri a. Blood. 2006 Oct 1;108(7):2159-64. doi: 10.1182/blood-2006-03-013086. Epub 2006 Jun 8. Blood. 2006. PMID: 16763209 Free article. Clinical Trial.
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.
Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Ladetto M, et al. Among authors: olivieri a. Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31. Blood. 2008. PMID: 18239086 Free article. Clinical Trial.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Cavo M, et al. Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Lancet. 2010. PMID: 21146205 Clinical Trial.
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A. Attolico I, et al. Among authors: olivieri a. Biol Blood Marrow Transplant. 2012 Feb;18(2):241-9. doi: 10.1016/j.bbmt.2011.07.014. Epub 2011 Jul 24. Biol Blood Marrow Transplant. 2012. PMID: 21791194 Free article. Clinical Trial.
718 results